INT24644
From wiki-pain
|
|
|
|
|
Sentences Mentioned In
Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
Slight changes in liver weight, cholesterol, HDL-cholesterol and glucose were observed in male and female animals. | |||||||||||||||
| |||||||||||||||
|
However, while there was a substantial reduction in triglycerides in the fibrate group at study end, there was essentially no effect on HDL-cholesterol. | |||||||||||||||
| |||||||||||||||
|
Effects on HDL-cholesterol were essentially identical between groups, with additional reductions in LDL-cholesterol and triglycerides arising from statin treatment.
| |||||||||||||||
| |||||||||||||||
|
Low HDL-cholesterol is an independent cardiovascular risk factor | |||||||||||||||
| |||||||||||||||
|
Statins remain the mainstay of lipid-modifying therapy according to current guidelines, but exert relatively little effect on HDL-cholesterol, as described above. | |||||||||||||||
| |||||||||||||||
|
Plasma levels of cholesterol, triglycerides, and LDL- and HDL-cholesterol did not show any significant alterations. | |||||||||||||||
| |||||||||||||||
|
The effects of NiaspanĀ® on HDL-cholesterol are essentially identical to those of immediate-release nicotinic acid. | |||||||||||||||
| |||||||||||||||
|
The mean value of HDL-cholesterol at the end of ARBITER 3 was similar in groups who had previously received placebo or NiaspanĀ® in ARBITER 2 (1.25 mmol/L [48.5 mg/dL] and 1.26 mmol/L [48.6 mg/dL], respectively). | |||||||||||||||
| |||||||||||||||
|
In types IIa, IIb and IV hyperlipoproteinaemia cholesterol, triglycerides, LDL-cholesterol and HDL-cholesterol were affected markedly stronger by procetofene and bezafibrate than by etofibrate retard. | |||||||||||||||
| |||||||||||||||
|
There were no changes in total or VLDL-triglycerides or total HDL-cholesterol. | |||||||||||||||
| |||||||||||||||
|
In conclusion, policosanol administered at 10 mg/day produces more advantageous changes in HDL-cholesterol and has a better safety and tolerability profile than lovastatin 20 mg/day. | |||||||||||||||
| |||||||||||||||
|
The associations of CD4 cell count and HIV-1 viral load were similar for the absolute value of HDL-cholesterol and for total cholesterol.
| |||||||||||||||
| |||||||||||||||
|
In comparison with baseline values, no significant change was observed in blood glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, creatinine, TBARS and TAP in placebo-treated group. | |||||||||||||||
| |||||||||||||||
|
Anandamide, OEA and PEA correlated positively (p < .05) with SAT leptin mRNA and free fatty acid during hyperinsulinaemic clamp, and negatively with SAT LPL activity and plasma HDL-cholesterol, which were all specifically altered in OBT2D subjects.
| |||||||||||||||
| |||||||||||||||
|
In non diabetic Japanese subjects, Tokunaga et al. [43] found that the -1535T/T genotype modulates lipid levels promoting lower serum triglyceride levels and higher HDL-cholesterol levels. | |||||||||||||||
| |||||||||||||||
|
Metabolic parameters including HbA1C, triglycerides, total cholesterol, HDL-cholesterol and CRP did not change in placebo group during the study.
| |||||||||||||||
| |||||||||||||||
|
On the basis of TC:HDL-cholesterol effects alone, 9% of CHD events would be prevented by replacement of TFA in Iranian homes with cis-unsaturated fats (8% by replacement with saturated fats). | |||||||||||||||
| |||||||||||||||
|
These data suggest that a moderate physical training may be sufficient to increase the antioxidative status and decrease the atherosclerotic index but appears to have little further effect on HDL-cholesterol. | |||||||||||||||
| |||||||||||||||
|
In contrast to hormone replacement therapy, raloxifene has no effect on HDL-cholesterol and PAI-1 and a lesser effect on HDL2-cholesterol and lipoprotein (a) (Walsh et al 1998). | |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.